BP15002
|
BAY 2416964
|
|
|
|
BAY 2416964 is a potent and orally active aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018146010A1 (example 192, IC50: 341 nM). It has the potential for cancer treatment.
|
BP15003
|
BBIQ
|
|
|
|
BBIQ is a powerful vaccine adjuvant that enhances innate immune responses and it is a imidazoquinoline compound and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC50 of 59.1 nM for human TLR7.
|
BP15004
|
Benralizumab
|
|
|
|
Benralizumab (MEDI-563) is an IL-5Rα-directed cytolytic monoclonal antibody that induces rapid, direct and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. It can be used for severe eosinophilic asthma.
|
BP15005
|
3-Oxobetulin
|
|
|
|
Betulone is a triterpenoid. It has a role as a metabolite. It derives from a hydride of a lupane.
|
BP15006
|
BF738735
|
|
|
|
BF738735 is a selective inhibitor of phosphatidylinositol 4-kinase III beta (PI4KIIIβ, IC50 = 5.7 nM) showing higher activity over α(IC50 = 1.7 μM). BF738735 exhibits a broad spectrum of antiviral activity.
|
BP15007
|
Bindarit
|
|
|
|
Bindarit displays specific inhibition against monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7 and MCP-2/CCL8.
|
BP15008
|
BMS CCR2 22
|
|
|
|
BMS CCR2 22 is a potent, specific and high affinity CC-type chemokine receptor 2 (CCR2) antagonist. It has excellent binding affinity (binding IC50 of 5.1 nM) and potent functional antagonism (calcium flux IC50 of 18 nM and chemotaxis IC50 of 1 nM).
|
BP15009
|
BMS-813160
|
|
|
|
BMS-813160 is the first dual CCR2/CCR5 antagonist to enter Clinical development for cardiovascular.
|
BP15010
|
BMS-905
|
|
|
|
BMS-905 is a potent dual inhibitors of TLR7 and TLR8 with good selectivity against TLR9 and other family members. BMS-905 can be used in studies about the treatment of diseases such as psoriasis, arthritis, and lupus.
|
BP15011
|
Bonafton
|
|
|
|
Bonafton is an antiviral agent.
|
BP15012
|
Brevifolincarboxylic acid
|
|
|
|
Brevifolincarboxylic acid is a natural product isolated from Polygonum capitatum, it has inhibitory effect on the aryl hydrocarbon receptor (AhR). Brevifolincarboxylic acid is an α-glucosidase inhibitor with an IC50 of 323.46 μM.
|
BP15013
|
Bropirimine
|
|
|
|
Bropirimine (U-54461) is a biological response modifier that is thought to act through the induction of lymphokines.
|
BP15014
|
Bunaprolast
|
|
|
|
Bunaprolast shows significant inhibition of lipoxygenase and TXB2 release. Bunaprolast is a potent inhibitor of LTB4 production in human whole blood.
|
BP15015
|
IRAK4-IN-7
|
|
|
|
CA-4948 (previously AU-4948) is a selective and potent IRAK4 kinase inhibitor with in vivo activity in a TLR4-induced cytokine release model.
|
BP15016
|
CAFESTOL
|
|
|
|
CAFESTOL is a ERK inhibitor for AP-1-targeted activity against PGE2 production and the mRNA expression of cyclooxygenase (COX)-2 in LPS-activated RAW264.7 cells. Cafestol has strong inhibitory activity on PGE2 production by suppressing the NF-kB activation pathway.
|
BP15017
|
Camalexin
|
|
|
|
Camalexin is a phytoalexin isolated from Camelina sativa. It has antifungal, antibacterial, antiproliferative, and anticancer activities. Camalexin can induce ROS production.
|
BP15018
|
Camstatin acetate
|
|
|
|
Camstatin acetate binds calmodulin and inhibits neuronal nitric oxide synthase. Camstatin acetate is a functionally active 25-residue fragment of the single calmodulin-binding IQ motif of PEP-19.
|
BP15019
|
Carbenicillin disodium
|
|
|
|
Carbenicillin Disodium is a broad-spectrum, semi-synthetic penicillin antibiotic with bactericidal and beta-lactamase resistant activity.
|
BP15020
|
Carbidopa monohydrate
|
|
|
|
Carbidopa Hydrate is an inhibitor of DOPA decarboxylase, preventing the conversion of levodopa to dopamine.
|
BP15021
|
Carbidopa
|
|
|
|
Carbidopa is an aromatic-L-amino-acid decarboxylase inhibitor (IC50: 29±2 μM). It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA.
|